An overall com- parison stratifying for prognostic groups yields a marginally significant advantage rves for patients random to maintenance therapy (x2 = 432, P= ive maintenance therapy 0X04).
← all excerpts
Treatment comparisons in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults.
1
—
—